Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register cannabis policycannabis lawfederal cannabisstate regulationDEA…
Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register cannabis policycannabis lawfederal cannabisstate regulationDEA…
DEA Places Four Synthetic Cannabinoids in Schedule I
The Drug Enforcement Administration has placed four synthetic cannabinoids into Schedule I due to their high abuse potential and lack of accepted medical use. These DEA Schedule I synthetic cannabinoids include 4F-MDMB-BUTICA, ADB-4en-PINACA,…
DEA Places Synthetic Cannabinoid CUMYL-PEGACLONE in Schedule I
The U.S. Drug Enforcement Administration has placed CUMYL-PEGACLONE, a synthetic cannabinoid analog, into Schedule I of the Controlled Substances Act due to its high abuse potential and lack of accepted medical use. This CUMYL-PEGACLONE Schedule I…
DEA Places 2-Fluorodeschloroketamine in Schedule I Controlled Substances
The DEA has temporarily placed 2-fluorodeschloroketamine in Schedule I of the Controlled Substances Act, reflecting regulatory action against emerging synthetic ketamine analogs. This DEA Schedule I classification demonstrates the federal approach to…
Policy Watch: 20 Regulatory Updates — June 08, 2026
Policy WatchJune 08, 2026. 20 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score. Score 70Federal RegisterSchedules of…
Policy Watch: 10 Regulatory Updates — June 02, 2026
Policy WatchJune 02, 2026. 10 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score. Score 70Federal RegisterSchedules of…
US DOJ Proposes Marijuana Reclassification: Federal Policy Shift
The marijuana reclassification federal policy proposed by the DOJ marks a significant shift in cannabis regulation. This change could enable expanded medical research and improve patient access. It reflects growing acceptance of cannabis's medical use at…
Medical Marijuana Reclassified as Less Dangerous Drug – WHIO-TV
The medical marijuana rescheduling impacts are significant for clinical research and policy development. This reclassification to Schedule III removes barriers to rigorous studies. Clinicians anticipate improved evidence-based cannabis medicine as a…
U.S. Department of Justice Issues Final Order Rescheduling Medical Cannabis to Schedule …
✦ New CED Clinical Relevance #76Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic Federal PolicyCannabis ResearchRegulatory…